Log in to search using one of your social media accounts:

 

Horizon Pharma plc to Acquire Worldwide Rights to Interferon Gamma-1b From Boehringer Ingelheim International GmbH
Also Licenses Rights to Patents and Pending Applications Covering Methods for Treating Friedreich's Ataxia With Interferon Gamma-1b; Company Currently Owns the Rights to Interferon Gamma-1b Under the Trade Name ACTIMMUNE(R) in the United States, Canada and... Biopharmaceuticals, Licensing, AcquisitionsHorizon Pharma, Boehringer Ingelheim, interferon gamma-1b (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 19, 2016 Category: Pharmaceuticals Source Type: news

Horizon Pharma completes patent enrolment for Phase lll trial of actimmuneto treat Friedreich's Ataxia
Ireland-based biopharmaceutical company Horizon Pharma has completed its target enrolment of 90 patients for Phase lll trial of actimmune (interferon gamma-1b) to treat Friedreich's Ataxia (FA) disease. (Source: Drug Development Technology)
Source: Drug Development Technology - May 5, 2016 Category: Pharmaceuticals Source Type: news

ACTIMMUNE (Interferon Gamma-1b) Injection, Solution [HZNP USA, Inc.]
Updated Date: Jun 12, 2015 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - June 12, 2015 Category: Drugs & Pharmacology Source Type: news

Horizon Pharma begins Actimmune’s Phase III trial for Friedreich's Ataxia
Ireland-based Horizon Pharma has started the Phase III study of Actimmune (interferon gamma-1b) to treat patients with Friedreich's Ataxia (FA), a degenerative neuro-muscular disorder. (Source: Drug Development Technology)
Source: Drug Development Technology - June 7, 2015 Category: Pharmaceuticals Source Type: news

Horizon Pharma plc Receives FDA Fast Track Designation for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia
DUBLIN, IRELAND--(Healthcare Sales & Marketing Network) - Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that a... Biopharmaceuticals, Neurology, FDAHorizon Pharma, ACTIMMUNE, Friedreich's Ataxia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 10, 2015 Category: Pharmaceuticals Source Type: news

Horizon Pharma plc Submits Investigational New Drug Application for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia
Phase 3 Study Expected to Begin in Q2 2015 DUBLIN, IRELAND--(Healthcare Sales & Marketing Network) - Horizon Pharma plc (HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commerci... Biopharmaceuticals, Neurology, FDAHorizon Pharma, ACTIMMUNE, Friedreich's Ataxia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2015 Category: Pharmaceuticals Source Type: news

ACTIMMUNE (Interferon Gamma-1b) Injection, Solution [InterMune, Inc.]
Updated Date: Jan 18, 2013 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - January 18, 2013 Category: Drugs & Pharmacology Source Type: news